Tectonic Therapeutic, Inc. (TECX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $27.28 (+0.26%), Market cap $0.52B, 52-week low–high $14.71 ~ $35.87.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Tectonic Therapeutic, Inc. are updated in real time on BlackAll Trade.
Tectonic Therapeutic, Inc. trades at $27.28 (+0.26%). Real-time quotes and charts are available on BlackAll Trade.
Tectonic Therapeutic, Inc. has a market cap of about $0.52B.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It